TCE-A
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
TCE-A: An "OR-gate" CD19×CD20×CD3 trispecific T-cell engager for B-cell malignancies and autoimmune diseases
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Trispecific • Hematological Malignancies • Oncology • CD20
1 to 1
Of
1
Go to page
1